All In Biotech

Drug Trial Radar · NCT05299697

A Study of TG103 Injection in Overweight or Obesity

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study of TG103 Injection in the Management of Overweight or Obesity

Last checked: Nov 19, 2026Latest source record: May 23, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 195 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

195

Planned (sponsor's estimate)

Start

May 20, 2022

Primary completion

Jun 30, 2023

Study completion Sep 30, 2023

Sponsor

Sponsor type
Industry
First posted
Mar 29, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multicenter, randomized, double-blind, placebo-controlled, parallel phase II study to evaluate efficacy, safety, pharmacokinetics characteristics and immunogenicity of two dose levels of TG103 injection, a GLP-1 receptor agonist, in the management of overweight or obesity, to support dose selection for further development.

Conditions

  • Overweight or Obesity

Interventions

  • TG103 15 mgDrug

    Administered subcutaneously (s.c., under the skin) as well as calorie restrict diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg to 15 mg.

  • TG103 22.5 mgDrug

    Administered subcutaneously (s.c., under the skin) as well as calorie restrict diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg, 15 mg to 22.5 mg.

  • PlaceboDrug

    Administered subcutaneously (s.c., under the skin) as well as calorie restrict diet and increased physical activity for 24 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Relative change from baseline in body weight at week 24Time frame: From baseline to week 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Baotou City Central Hospital

    Baotou, Neimenggu, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.